VERU - Veru jumps 19% ahead of FDA AdCom meeting on COVID-19 therapy

• Veru Inc. ( NASDAQ: VERU ), a biopharma targeting cancer, added 19% pre-market Monday as the company is set to face an FDA's Advisory Committee meeting this week regarding its marketing application for the oral COVID-19 therapy sabizabulin.
• The regulator is expected to publish the briefing documents on Monday ahead of the Nov. 09 meeting of its Pulmonary-Allergy Drugs Advisory Committee.
• The FDA's AdCom panels issue non-binding recommendations. However, the regulator usually follows them before making a final decision on authorizations.
• VERU shares fell on Sep. 07 after the FDA first scheduled the meeting to discuss the emergency use authorization (EUA) application for sabizabulin on Oct. 06. However, several days later, the agency postponed the meeting to Nov. 06.

For further details see: